(Reuters) - Mallinckrodt Plc said on Tuesday it would spin off its generic drugs business as a separate unit and keep constipation medicine Amitiza as part of its specialty branded drugs business, ...

SAN DIEGO, May 18 /PRNewswire/ -- New study results indicated that treatment with AMITIZA(R) (lubiprostone) 8 mcg lead to significant relief of overall symptoms of Irritable Bowel Syndrome with ...

BETHESDA, Md., and DEERFIELD, Ill., May 27 Sucampo Pharmaceuticals, Inc. (Nasdaq: SCMP) and Takeda Pharmaceuticals NorthAmerica, Inc. today announced that AMITIZA(R) (lubiprostone) 8 mcg capsulesare ...

SAN FRANCISCO, CA--(Marketwired - Feb 23, 2016) - The Amitiza (Irritable Bowel Syndrome) market had more than USD 655.0 million in 2010 and is anticipated to rise at a CAGR of more than 11.0% over the ...

DUBLIN, Jan. 4, 2021 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) announced today that one of its operating companies, Par Pharmaceutical, Inc. (Par), has begun shipping the first authorized ...

Amitiza (lubiprostone) is a brand-name oral capsule that’s prescribed for constipation in adults. The cost of the drug, with and without insurance, can depend on several factors, such as whether ...

Takeda Pharmaceuticals North America launched its first DTC ad campaign for chronic constipation drug Amitiza, targeting women 40 and over with TV and print ads featuring the tagline: “Move to Amitiza ...

For the majority of drugs, end-of-lifecycle planning usually involves a reining-in of marketing costs. But Sucampo CEO Peter Greenleaf is doing the exact opposite. In the firm’s second-quarter ...

Please provide your email address to receive an email when new articles are posted on . Amitiza, a novel type 2 chloride channel activator, increased the frequency of spontaneous bowel movement and ...

In recent studies, AMITIZA (tm)(lubiprostone) demonstrated improvements in relief of symptoms associated with irritable bowel syndrome with constipation (IBS-C), such as abdominal bloating and ...

Results of a secondary analysis of two pivotal studies were presented today at the 71st Annual Meeting of the American College of Gastroenterology (ACG), and showed that 60 percent of patients treated ...